National Cancer Institute

UPDATE FROM NCI

SITC ANNUAL MEETING
OCTOBER, 2012

William Merritt
Program Director
CGCB/DCTD
National Cancer Institute

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Trend in RPGs funded



Funding of RPGs



FY 2011 Funded Grants

FY 2011 Budget: $5.058 million
43% for RPG pool

T1/2 R01s:	**1st to 7th percentile:**	**342**
	8th to 15th % plus:	**316**
Other RPGs:		**448**
	Total:	**1106**



Source: NCI Factbook 2011

Second Level Evaluation of R01s above Payline

- "Payline" at 7 percentile for FY11 and FY12
- 8-15 percentile and/or impact score generaly less than 30 can be brought forward for further consideration

- Rationale: Grants above "best of the best" need to be prioritized to fill gap in NCI grants portfolio and/or have especially novel and/or promising approach: now a broad range of applications considered

- PD prepares justification for funding
- Rank-ordered in Programs and then Divisions
- Final decisions at Senior Leadership meeting (Division leaders with NCI director)

FY12 and FY13

- FY12
  - 5.07 Billion (increase 12 million from FY11)
  - Approximately same number of R01s as FY11
  - 17% cut in budgets in funded competing grants
  - Non-competing: no COLA (2% cut from committed)
- FY13
  - Continuing resolution until March 2013 (holding our breath regarding new budget)
  - "Payline" (most likely to be funded) has been extended to 9% from 7%
  - Range of scores for "consideration" outside of the payline not announced but expected to be similar to FY12

Immunotherapy Grants in CTEP: Hem Malignancies

Disease	R01	P01	R21	R00
Multiple Myeloma	0	3		
Lymphoma	1	2		
NHL	1	0		
Hodgkin	0	1		
Mantle Cell	0	0		1
Leukemia	0	2	1	
Myeloid	0	1		
ALL	1	0		
CLL	1	1		
CML	0	1		
Multiple Hem	0	2		
TOTAL	4	13		

Immunotherapy Grants in CTEP: Solid Tumors

Disease	R01	P01	R21	U01
Melanoma	4	4		
Brain	4	4		
Breast	4	0		
Pancreatic	1	0		
Renal	1	0		
Prostate	1	0		
Ovarian	1	0	1	
Hepatocellular	1	0		
Neuroblastoma	1	2	1	
Colorectal	0	1		
Thorasic	0	1		
Nasopharyngeal	0	1		
Multiple	1	4		1
Total	19	17	2	1

Agents Currently under Study in the Cancer Immunotherapy Trials Network

Rank	Agent	Category	Source	Status
1	IL-15	T cell growth factor	NCI/BRB	Approved protocol
1a	IL-15/ IL15Rα	T cell growth factor	Altor	LOI submission to CTEP shortly
3	Anti-PD1/PDL1	T cell checkpoint inhibitor	Under active negotiation	Concepts (4) anti-PDL1 developed
4	Anti-CD40	APC stimulator	Pfizer	Study opened for accrual!
5	IL-7	T cell growth factor	Cytheris	1 combination trial protocol in CTEP review; 2nd concept in development
7	1- MT or alternate	IDO inhibitor	Incyte	2 studies: 1 LOI CTEP approved, 1 in review
10	Anti-IL10	Suppression inhibitor	Under active negotiation	Concepts (2) developed
11	Flt3-L	DC growth factor	Celldex	Concept developed and LOI written

Immunotherapy Agents from CTEP

- Anti-CTLA4 (ipilimumab)
  - 58 LOIs received
    - 10 approved/4 in review
    - Diverse solid tumors plus 3 Hematologic
  - 8 concepts received
    - (3 approved/3 in review)
    - Melanoma (4); Glioblastoma/Astocytoma (2)
- IL-15
  - 4 INDs open including CITN
  - Not accepting LOIs now until Phase I results received
- IL-12; 2 LOIs approved

Potential Agents from CTEP

- Agents:
  - Anti-PD1
  - IDO inhibitor (1-MT or alternate)
  - Pomalidomide
- Agents under review after preliminary discussions with companies (no CRADA)

Agents in Production Stages Biological Resources Branch/NCI

- rhIL-15 (supplement current lots)
- ch14.18 anti-GD2 monoclonal antibody
- hIg-4-1BBL (tox lot production)
- rhIL-7
  - Potential replacement for company as supplier
  - Under discussion
- Contact Dr. Steve Creekmore (creekmores@mail.nih.gov)

Agents for Pre-clinical Studies Biological Resources Branch

- Cytokines: IL-15, IL-7, IL-12
- Vaccine adjuvant: MPL (monophosphoryl Lipid A)
- Ligands: CD40 Ligand
- Chemokines: Adv-CCL21
- Anti-ganglioside antibodies: Anti-GD2 (ch.14.18, hu14.18-IL2, 1A7) and Anti-GD3 (R24, stock)
- Other antibodies and cytokines in BRB repository: http://web.ncifcrf.gov/research/brb/default.aspx

- Contact Karen Muszynski for NCI 2007 prioritized agents and anti-GD2 Abs
- Order Stock Reagents through BRB website



NCI EXPERIMENTAL THERAPEUTICS (NEXT) PROGRAM

Barbara Mroczkowski, Ph.D.
Special Assistant to the Deputy Director for Clinical and Translational Research
Executive Secretary, NCI Experimental Therapeutics Program
National Cancer Institute
mroczkowskib@mail.nih.gov

Transformation of the NCI Therapeutics Pipeline

Cancer Centers
SPORE
DDG
NIH Roadmap MLPCN
Imaging
RO1/PO1
Intramural PIs (CCR)
RAID
Biotech and Pharma

Harmonize Activities into Single Pipeline

Drug Discovery | **Early Development** | **Full Development**

***September 15th 2009*: Cycle 1 Solicitation of Applications**

Eligibility: US and International Researchers from Academia, Industry, and Non-profit Organizations

349 Submissions Received to Date



First cycle reviewed in December 2009

*** Cycle 11 under review**

Current NExT Pipeline



9 NExT-initiated projects have been discontinued

Portfolio Stratified by Agent Class



Projects that are closed or awaiting resourcing are not included

Access to NExT

http://next.cancer.gov

Clinical Assay Development Program (CADP)

- Purpose: Provide services to facilitate moving potential clinical marker assay to validated biomarker
- Come in after assay in hand but before development
- Testing assay performance using retrospective samples
- Assay optimization: controls, analytical parameters, lot acceptance criteria
- Statistical support to assist in assay clinical validation
- Integral vs. integrated assays preferred
- Link to Phase III vs. Phase II preferred
- Contact: Dr. M. Thurin (thurinm@mail.nih.gov)

Omnibus R21 (PAR-17-145)

- Purpose: Exploratory/Developmental Projects, pilot studies
- No restrictions on topics (includes clinical research)
- Budget: $275K direct costs ($200K, any 1 yr)
- May, 2012: first submission date (standard receipt dates apply)
- Review in NCI, but will be percentiled with other CSR-reviewed R21s

Cancer Biomarkers PAs

- **R01** (PA-12-013) and **R21** (PA-12-014)
- "Validation of Molecular Diagnostics to Predict Outcomes using Specimens from Multi-site Cancer Trials"
- Purpose: to transition candidate biomarkers from initial observations to a marker suitable for use for determining prognosis or predicting response to therapies
- Standard receipt dates apply
- Contact: Drs. Magdalena Thurin (DCTD/CDP) or Min Song (DCTD/CTEP)